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Abstract
It is unclear whether the cellular origin of various forms of pancreatic cancer involves transformation or transdifferentiation
of different target cells or whether tumors arise from common precursors, with tumor types determined by the specific
genetic alterations. Previous studies suggested that pancreatic ductal carcinomas might be induced by polyoma middle T
antigen (PyMT) expressed in non-ductal cells. To ask whether PyMT transforms and transdifferentiates endocrine cells
toward exocrine tumor phenotypes, we generated transgenic mice that carry tetracycline-inducible PyMT and a linked
luciferase reporter. Induction of PyMT in b cells causes b-cell hyperplastic lesions that do not progress to malignant
neoplasms. When PyMT is de-induced, b cell proliferation and growth cease; however, regression does not occur,
suggesting that continued production of PyMT is not required to maintain the viable expanded b cell population. In
contrast, induction of PyMT in early pancreatic progenitor cells under the control of Pdx1 produces acinar cell carcinomas
and b-cell hyperplasia. The survival of acinar tumor cells is dependent on continued expression of PyMT. Our findings
indicate that PyMT can induce exocrine tumors from pancreatic progenitor cells, but cells in the b cell lineage are not
transdifferentiated toward exocrine cell types by PyMT; instead, they undergo oncogene-dependent hyperplastic growth,
but do not require PyMT for survival.
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Introduction
The pancreas is a key regulator of glucose homeostasis and of
protein and carbohydrate digestion [1]. It is composed of two major
compartments, the endocrine pancreas and the exocrine pancreas.
The endocrine pancreas, which regulates metabolism and glucose
homeostasis, consists of five hormone-expressing cell types – a, b, d,
e, and pp cells – that produce glucagon, insulin, somatostatin,
ghrelin, and pancreatic polypeptide, respectively. Endocrine cells
are arranged in clusters, called the islets of Langerhans, and most of
the cells in each islet are b cells [2]. The exocrine pancreas is
composed of the digestive enzyme-producing acinar cells and a
branching network of ducts that direct the enzymes to the intestines.
A spectrum of pancreatic malignancies possess histological and
molecular features that recapitulate to some degree the properties
of their normal cellular counterparts, and rare pancreatic tumors
with mixed differentiation have also been described [1,3]. The
cellular origins of pancreatic cancers have been debated. It is not
clear whether different pancreatic tumor types arise from
transformation of different target cells, from transformation
followed by transdifferentiation, or from transformation of a
common precursor, with the phenotypes determined by the
differentiation effects of specific genetic alterations. Pancreatic cells
have been shown to be susceptible to transdifferentiation: by
ectopic expression of transcription factors in vivo, adult b cells can
be transdifferentiated into a and pp cells [4], and exocrine cells
can be transdifferentiated into b cells [5].
An early study indicated that murine pancreatic ductal
adenocarcinomas can be generated by in vitro transduction of
polyoma middle T antigen (PyMT) into the islets prepared from
juvenile mice, but not from aged mice [6]. A subsequent report
from our laboratory showed that delivery of an avian leukosis-
sarcoma virus (ALSV)-based vector encoding PyMT or cMyc to
newborn elastase-tva; Ink4a/Arf-null transgenic mice, in which the
receptor for subgroup A avian leukosis virus, TVA, is expressed in
multiple pancreatic cell types, induces different pancreatic lesions
[7]. In those experiments, PyMT induced cystic papillary
neoplasms with ductal differentiation and pancreatic intraepithe-
lial neoplasia (PanIN) lesions, as well as carcinomas with mixed
acinar and endocrine components, whereas cMyc induced
endocrine neoplasms that express insulin. We could not determine,
however, whether PyMT transforms multipotential progenitor
cells, possibly including islet cell precursors, and guides them
toward exocrine cell fates, or whether PyMT transforms only the
cells that are already committed to exocrine cell fates.
To distinguish between these possibilities, we generated
transgenic mouse lines with a tetracycline-inducible PyMT
oncogene that could be turned on and off in different cell types
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transgene encoding a tetracycline-dependent regulatory protein
under different cell-specific promoters. A luciferase reporter was co-
activated in the PyMT transgene, so that transgene expression
could be detected by in vivo bioluminescent imaging. Although
PyMT is not implicated in human cancer, it remains an important
experimental tool because its product is a potent oncoprotein, and
stimulates at least two signaling pathways that are important in
human cancers – the mitogen-activated protein kinase (MAPK)
and phosphatidylinositol 3-kinase (PI3K) cascades [8].
Our studies suggest that the ability of PyMT to induce
tumorigenesis is dependent upon the types of the pancreatic cells
in which it is expressed. Conditional activation of PyMT in b cells
led to irreversible non-malignant expansion of the b cell population,
regardless of the developmental stage at which it was expressed.
However, activation of PyMT in the common precursors of both
exocrine and endocrine pancreatic cells induced lethal acinar cell
carcinomas in some mice, as well as b-cell hyperplasia. Further-
more, although continued expression of PyMT is required for the
survivaloftheacinarcellcarcinomacells,asistrueformanytypesof
oncogene-induced neoplasms in mice [9,10], it is not required to
sustain the survival of the hyperplastic b cells.
Results
Generation of mice with a Tet-regulated PyMT oncogene
To generate mice in which we could regulate the expression of
PyMT in the pancreas, we used the tetracycline regulatory system. A
tet-o-PyMT-IRES-Luc responder transgene was constructed carrying
the PyMT gene downstream of tet operator sequences (details in
Materials and Methods). To facilitate detection of transgene
expression, this 5.8 kb piece of DNA encodes a bicistronic mRNA
consisting of a luciferase reporter gene translated from an internal
ribosome entry site (IRES) downstream of the PyMT coding region.
Seven tet-o-PyMT-IRES-Luc transgenic founders (#1, 2, 20, 21, 23,
29, and 39) were identified by PCR genotyping among the 39 pups
obtained from the microinjection of this transgene into C57BL/6
mouse eggs, and the transgene was transmitted to the progeny of all
7 founder lines. However, founder line #20 expressed luciferase
ubiquitously without a tetracycline regulatory protein, as deter-
mined by in vivo bioluminescent imaging (data not shown). This line
was not evaluated further.
Activation of PyMT induces hyperplasia in the b cells of
RIP-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice
We first determined the consequences of expressing the PyMT-
IRES-Luc transgene exclusively in b cells of the pancreas. Milo-
Landesman et al. (2001) previously described mice bearing a
transgene, RIP7-rtTA, expressing the reverse tetracycline trans-
activator protein (rtTA) in b cells under the control of the rat insulin
promoter (RIP). These mice were crossed to our 6 founder lines, so
that the PyMT-IRES-Luc transgene could be induced by doxycy-
cline, an analog of tetracycline, specifically in b cells. Some of the
resulting bitransgenic mice, were placed on a diet containing
doxycycline at 4 weeks of age, monitored for the expression of the
PyMT-IRES-Luc transgenebyinvivobioluminescentimagingweekly,
and sacrificed at various ages for histological examination. We
focused on RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice
derived from 2 founder lines (#21 and 29), in which the transgene
was tightly regulated, as indicated by bioluminescence (Figure 1A
and data not shown). These bitransgenic mice exhibited luciferase
activity (10
6 to 10
7 photons/sec) from the area over the pancreas
after being placed on a diet containing doxycycline for 1 day. We
observed some enlarged islets histologically after 2 weeks on
doxycycline (data not shown). After 4 months on doxycycline, the
bitransgenic mice still displayed luciferase activity (10
6 to 10
7 pho-
tons/sec; Figure 1A). None of RIP-rtTA and tet-o-PyMT-IRES-Luc
mono-transgenic mice on doxycycline or the bitransgenic mice
without doxycycline displayed detectable luciferase activity
(Figure 1A). Immunohistochemical staining showed that the islets
were enlarged 29.5-fold on average in RIP7-rtTA; tet-o-PyMT-IRES-
Luc bitransgenic mice receiving doxycycline for 4 months, and most
of the cells in the enlarged islets were positive for insulin (Figure 1B,
C). Detailed histological examination revealed no abnormality in
other tissues from RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic
mice that received doxycycline for a year (data not shown).
To test whether the number of endocrine cells other than b cells
also increased in the enlarged islets, we performed immunohisto-
chemical staining with antisera against glucagon, somatostatin,
and pancreatic polypeptide. a, d, and pp cells persisted in the
enlarged islets from the bitransgenic mice on doxycycline for 4
months, but their numbers were not greater than those in the
normal islets from the bitransgenic mice without doxycycline
(Figure 1C and data not shown). The results suggest that the
enlarged islets result from PyMT-stimulated growth solely of
insulin-expressing b cells.
Adult islet cells in un-induced control RIP7-rtTA;tet-o-PyMT-IRES-
Luc bitransgenic mice had a low proliferation index of less than 0.5%,
as determined by nuclear staining for the cell proliferation marker,
Ki67 (Figure 1C). PyMT-induced b-cell hyperplasia was accompa-
nied by a proliferation index of 3.761.5% (Figure 1C). Despite b-cell
hyperplasia, the mice did not develop neoplasms or exhibit significant
hypoglycemia (blood glucose levels=176641 mg/dL in 7 RIP7-
rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice on doxycycline for 1
year vs. 184622 mg/dL in 6 age-matched non-transgenic mice). We
conclude that PyMT is able to induce hyperplasia in b cells and that
cells in the b cell lineage can respond to PyMT by undergoing
proliferative changes with retained endocrine, rather than exocrine,
features. The hyperplastic cells do not change normal homeostatic
control of glucose levels and do not progress to frank malignancy of
either endocrine or exocrine types.
In these initial experiments, the PyMT-IRES-Luc transgene was
induced only after weaning. To test whether the effects of PyMT
depended on the developmental stage of the b cell lineage at which
it was expressed, we induced the oncogene at an early stage of
pancreatic development. Animals mated to generate RIP7-rtTA;
tet-o-PyMT-IRES-Luc bitransgenic mice received dietary doxycy-
cline to allow induction of the transgene during pancreatic
organogenesis throughout embryonic development in pregnant
females; the resulting bitransgenic progeny were also maintained
on doxycycline. The rat insulin promoter is normally activated
around day E9.5 [11], and doxycycline is able to cross the placenta
and to accumulate in the milk of lactating females [12]; we
therefore presume that PyMT was produced in b cells during the
latter half of embryogenesis and early postnatal development in
bitransgenic progeny. However, when sacrificed at 6 months or 1
year of age, the pancreata of the bitransgenic progeny did not
appear different histologically from those in bitransgenic animals
that received doxycycline only after weaning; they exhibited
enlarged hyperplastic islets composed of mostly insulin-positive b
cells (6 mice at each time point, data not shown). Our results
suggest that the PyMT oncogene cannot transdifferentiate b cells
or any insulin-producing precursor to an exocrine phenotype or
cause progressive neoplasia, regardless of the stage of development
at which the oncogene is expressed.
In hopes of promoting tumorigenesis from b-cell hyperplasia,
RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice were also
crossed to Ink4a/Arf-null or Arf-null mice (n=12, for each group).
Differential Effects of PyMT
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e6932Figure 1. Expression of the PyMT-IRES-Luc transgene in the pancreata of RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice resulted in b-
cell hyperplasia. (A) Transgene expression in RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice monitored by in vivo bioluminescent imaging.
Control RIP7-rtTA and tet-o-PyMT-IRES-Luc mono-transgenic mice, and RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice that were and were not on a
doxycycline diet for 4 months were subjected to bioluminescence. Significant luciferase activity was detected in the area over the pancreas only in
the bitransgenic mouse on doxycycline (induced). The images are representative of more than 10 mice from each group. (B) Total area of islets in
RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice that were not on doxycycline (un-induced) compared with islet area in animals that received
doxycycline at 4 weeks of age for 4 months (induced). The area of the islets was determined from histological slides of insulin-stained pancreatic
sections, using Leica Application Suite 3.1.0. (C) Representative stained slides of enlarged, insulin-positive islets from RIP7-rtTA; tet-o-PyMT-IRES-Luc
bitransgenic mice that received doxycycline. Immunohistochemical staining for insulin, glucagon, somatostatin, and Ki67 in pancreatic sections from
RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice that were not on doxycycline (un-induced, left panels) and from those that received doxycycline for 4
months (induced, right panels). Original magnification, 206. The images are representative of more than 5 mice from each group.
doi:10.1371/journal.pone.0006932.g001
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these mice at 6 months of age that were kept on doxycycline
revealed no b-cell tumor formation (data not shown).
PyMT also induces b-cell hyperplasia when regulated by
a Pdx1-tTA transgene
We were surprised to find that the highly potent PyMT
oncoprotein failed to cause neoplastic changes in b cells. To
attempt to confirm this finding and rule out the possibility that
transdifferentiation to any non-b cell phenotype will repress the
expression of PyMT from the rat insulin promoter, we took
advantage of Pdx1-tTA knock-in mice, that express the tetracycline
trans-activator protein (tTA, which acts positively on the tet
operator in the absence of doxycycline) under the control of the
endogenous pancreatic and duodenal homeobox 1 (Pdx1)
promoter [13]. Pdx1-positive precursor cells of the early
embryonic pancreas give rise to all epithelial lineages of the
pancreas [14], but after birth Pdx1 is expressed at high levels in b
cells and at lower levels in some exocrine cells [15]. Moreover,
Pdx1 is upregulated in PyMT-induced ductal and acinar tumors in
elastase-tva; Ink4a/Arf-null transgenic mice [7], suggesting that the
Pdx1 promoter remains active in the exocrine tumors.
To express PyMT postnatally in Pdx1-tTA; tet-o-PyMT-IRES-Luc
mice, we placed mice pregnant with bi-transgenic progeny on
doxycycline, then activated PyMT in the bitransgenic progeny at
three weeks of age by removal of doxycycline. When these animals
were sacrificed at 21 weeks of age for histological examination of
the pancreas, we found b-cell hyperplasia indistinguishable from
that observed in RIP7-rtTA; tet-o-PyMT-IRES-Luc mice on
doxycycline and no other types of lesions were observed (data
not shown). These findings confirm that the PyMT oncogene
cannot transdifferentiate b cells to an exocrine phenotype, and
that b cells have an intrinsically different response to PyMT than
observed in mammary glands, endothelial cells, exocrine pancreas,
and liver, in which PyMT acts as a strong oncogene [7,16,17].
Induction of PyMT by Pdx1-tTA in pancreatic progenitor
cells induces lethal acinar cell carcinomas, in addition to
b-cell hyperplasia
To ask whether PyMT could cause exocrine lesions as well as
endocrine lesions when expressed starting from pancreatic
progenitor cells, we took advantage of the fact that Pdx1-tTA is
expressed in progenitor cells early in pancreatic development, as
well as in both exocrine and endocrine compartments postnatally.
Mice pregnant with Pdx1-tTA; tet-o-PyMT-IRES-Luc embryos and
the resulting bitransgenic progeny (a cohort of 50 mice) were
maintained on a doxycycline-free diet so that PyMT would be
expressed throughout pancreatic development and postnatal life.
These animals were tested for bioluminescence bi-weekly after 6
weeks of age, and formed two groups according to the strength of
luciferase signals and types of pancreatic lesions (Figure 2A).
More than 90% of the Pdx1-tTA; tet-o-PyMT-IRES-Luc bitrans-
genic mice (45 of 50; ages between 4 months to 1 year) maintained
onadoxycycline-freediet exhibitedmoderateluciferaseactivity(10
6
to 10
7 photons/sec) and had enlarged islets composed mainly of
insulin-expressing b cells (Figure 2A ¸ middle row). The histological
findings were similar to the b-cell hyperplasia observed when PyMT
was induced postnatally in Pdx1-tTA; tet-o-PyMT-IRES-Luc mice and
in RIP7-rtTA; tet-o-PyMT-IRES-Luc mice with doxycycline (data not
shown). Again, when 12 of these mice were examined at 1 year of
age, no frank islet neoplasms were found (data not shown).
In contrast, 4 of the 50 mice showed very high luciferase activity
(.10
8 photons/sec) and developed palpable and ultimately lethal
pancreatic tumors at various times (7,30 weeks of age; Figure 2B).
These tumors had histologic features of acinar cell carcinomas and
expressed chymotrypsin, an enzyme produced by acinar cells of the
pancreas (Figure 2A ¸ third row), suggesting that PyMT had induced
acinarcell carcinomas in these animals. These acinarcell neoplasms
were histologically and immunohistochemically indistinguishable
from their spontaneous human counterparts [18]. In contrast to the
tumors induced by PyMT in the elastase-tva; Ink4a/Arf-null model of
Lewis et al. [7], these acinar cell carcinomas in Pdx1-tTA; tet-o-
PyMT-IRES-Luc mice completely lacked endocrine differentiation
by immunohistochemistry.Furthermore, the tumors did not express
insulin or a ductal marker, mucicarmine (Figure 2A and data not
shown). These tumors were highly proliferative, with 46.7612%, of
the cells positive for Ki67 and tumor cells stained strongly for
phospho-S6 ribosomal protein as revealed by immunohistochem-
istry (Figure 2A). Acinar cell neoplasms overwhelmed the entire
pancreas, and normal pancreatic parenchyma including islets could
not be found in these 4 animals. However, one other animal had
relatively small acinar cell carcinomas co-existing with b-cell
hyperplasia (data not shown).
PyMT is not required to maintain the expanded b cell
population
To determine whether PyMT has a role in maintaining, as well
as in initiating, b-cell hyperplasia, we de-induced PyMT and
luciferase by withdrawing doxycycline from the diet of RIP7-rtTA;
tet-o-PyMT-IRES-Luc bitransgenic mice that had received doxycy-
cline for 4 months. We initially monitored the activity of the
luciferase reporter, using bioluminescence, and then performed
Western blots on protein extracts from islets to document the levels
of PyMT protein. We found that, within 3 days after removal of
doxycycline, luciferase activity dramatically declined (Figure 3A),
and no PyMT protein was detectable in the islets 2 weeks after
removal of doxycycline (Figure 3B); these findings indicate that the
expression of PyMT and luciferase was efficiently down-regulated.
When the pancreata were examined histologically, however,
enlarged islets composed of insulin-positive cells were still present 2
weeks after withdrawal of doxycycline (PyMT de-induced;
Figure 4A). Furthermore, no apoptotic cells were detected in the
enlarged islets by immunohistochemical staining for activated
caspase 3 between 1 and 14 days following withdrawal of
doxycycline (Figure 4B), indicated that the viability of the
hyperplastic b cells was not dependent on continued production
of the oncoprotein. However, cell proliferation and growth were
diminished; cells in the enlarged islets stained less intensely with
antisera against Ki67 and phospho-S6 ribosomal protein (Figure 4
C, D). The islets remained enlarged for at least three months after
withdrawal of doxycycline (data not shown), further suggesting that
hyperplastic b cells do not require PyMT to remain viable, even
though PyMT is required for continued proliferation. In addition,
the blood glucose levels of these mice did not change significantly
after withdrawal of doxycycline (data not shown), indicating that
PyMT did not modulate the expression of rtTA or insulin.
We confirmed these unexpected findings of oncogene-indepen-
dent survival of the hyperplastic cells using Pdx1-tTA; tet-o-PyMT-
IRES-Luc bitransgenic mice. Twelve such mice with moderate
luciferase activity (10
6 to 10
7 photons/sec) on a doxycycline-free
diet were given doxycycline to turn off the expression of transgene
(de-induced), and then imaged and sacrificed 1 day to 2 months
later. After a 1-day of de-induction, luciferase activity returned to
background levels as measured by bioluminescence, but enlarged
b-cell islets remained up to at least 2 months after de-induction
(data not shown). Thus, regardless of whether Pdx1-tTA or RIP-
rtTA is used to regulate expression of the inducible PyMT,
Differential Effects of PyMT
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the expanded b cell population, only for persistent growth.
PyMT is required for maintenance of acinar carcinomas in
Pdx1-tTA; tet-o-PyMT-IRES-Luc bitransgenic mice
PyMT and other oncoproteins are known to be required to
maintain the viability of cancer cells they induce [9,10]. In view of
our findings with PyMT-induced b-cell hyperplasia, we deter-
mined whether the survival or proliferation of PyMT-induced
acinar cell carcinoma cells depended on continued expression of
PyMT. To do this, we identified 8 Pdx1-tTA; tet-o-PyMT-IRES-Luc
bitransgenic mice with strong luciferase activity (.10
8 photons/
sec) and palpable pancreatic acinar cell carcinomas, and placed
them on a doxycycline-containing diet to turn off the expression of
Figure 2. Pdx1-tTA; tet-o-PyMT-IRES-Luc bitransgenic mice develop b-cell hyperplasia or lethal acinar cell carcinomas when PyMT is
expressed during and after pancreatic development. (A) Immunohistochemical staining was used to detect the expression of differentiation
markers (insulin and chymotrypsin), Ki67, and phospho-S6 ribosomal protein (pS6) in normal pancreas, b-cell hyperplasia from 1-year-old Pdx1-tTA;
tet-o-PyMT-IRES-Luc bitransgenic mice that were never on doxycycline (induced), and acinar cell carcinomas from 7 or 17-week-old Pdx1-tTA; tet-o-
PyMT-IRES-Luc bitransgenic mice that were never on doxycycline (induced). Bar: 50 mm. (B) Representative normal pancreas and spleen from a non-
transgenic animal (left) and acinar cell carcinomas and spleens from two 7.5-week-old Pdx1-tTA; tet-o-PyMT-IRES-Luc bitransgenic mice that were
never on doxycycline (middle and right). s: spleen.
doi:10.1371/journal.pone.0006932.g002
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day to 15 weeks later to assess the response of tumor cells to de-
induction of PyMT. One to 4 days after de-induction, we observed
a large reduction of luciferase activity by bioluminescence
(Figure 5A). Two weeks after de-induction, the acinar neoplasms
were no longer palpable. The tumors were still grossly visible when
mice were sacrificed at this time (Figure 5B, third panel), but they
gradually regressed and the pancreata returned to a normal
histological appearance over the course of 15 weeks (Figure 5B,
fifth panel). Mostly normal-sized islets were observed in the
regenerated pancreata after the acinar cell carcinomas regressed.
Apoptotic cells, as identified by the TUNEL assay, and loss of
Ki67
+ cells were observed in the regressing acinar cell carcinomas
(data not shown). Our observations, in concert with many
published studies [9,10], strongly suggest that PyMT is required
to maintain cell viability in PyMT-induced pancreatic acinar cell
carcinomas.
Discussion
We have generated tetracycline-inducible PyMT transgenic
mice to investigate the consequence of activating PyMT
oncogene in different cell types in the pancreas and at
different developmental stages. To facilitate transgene detection
in vivo,w ep l a c e daluciferase reporter gene behind IRES
downstream of PyMT. Induction of PyMT in the pancreatic b
cell lineage in RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic
mice resulted in b-cell hyperplasia regardless of their
developmental stages. b-cell hyperplasia was also induced in
Pdx1-tTA; tet-o-PyMT-IRES-Luc bitransgenic mice, and the
insulin-expressing b-cell hyperplasia does not further progress
to form frank neoplasms even after 1 year of oncogene
activation and in Ink4a/Arf-null and Arf-null backgrounds.
Upon de-induction of PyMT, the proliferation was greatly
reduced in these hyperplastic islets. Nevertheless, no apoptotic
Figure 3. Reduction of luciferase activity and PyMT protein levels after withdrawal of doxycycline from the diet of RIP7-rtTA; tet-o-
PyMT-IRES-Luc bitransgenic mice. (A) Studies with RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice that had been fed doxycycline for 4 months
before doxycycline was removed for 1, 2, and 3 days. Upper panels show in vivo bioluminescent images acquired from a single RIP7-rtTA; tet-o-PyMT-
IRES-Luc bitransgenic mouse. Lower panel shows results with 5 mice; each mouse is represented with a different symbol. (B) SDS-PAGE and Western
blotting were used to determine the levels of PyMT proteins, detected with an antiserum against PyMT, in whole cell extracts of isolated islets of a
RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mouse that received doxycycline for 4 months (left lane; induced) and a bitransgenic mouse that had
received doxycycline for 4 months and off doxycycline for 2 weeks (right lane; de-induced). A portion of nitrocellulose membrane stained with
Ponceau S was shown as a loading control.
doi:10.1371/journal.pone.0006932.g003
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induction of PyMT, and the islets remained enlarged once they
were expanded, even when PyMT was de-induced.
A few (less than 10%) of Pdx1-tTA; tet-o-PyMT-IRES-Luc
bitransgenic mice developed lethal acinar cell carcinomas in
adulthood when the PyMT transgene was induced during
Figure 4. Effects of de-induction of PyMT on the enlarged islets of RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice. Sections of
pancreata from RIP7-rtTA; tet-o-PyMT-IRES-Luc bitransgenic mice that were never on doxycycline (un-induced) or mice that were placed on
doxycycline at 4 weeks of age for 4 months, with removal of the inducer for 1 day, 3 days, or 2 weeks, were stained with antibodies against insulin (A),
activated caspase 3 (B), Ki67 (C), and pS6 (D). The proliferation indices of the islets indicated in (C) are the average of the percentage of Ki67
+ cells
from at least 5 islets under 406magnification at each time point. Sections of spleens, which contain apoptotic cells, were used as a positive control
for activated caspase 3 staining, at the bottom of the figure. Original magnification, 206.
doi:10.1371/journal.pone.0006932.g004
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resemble their spontaneous human counterparts. Because no
exocrine tumors were observed when the PyMT transgene was
induced postnatally, we concluded that early precursor cells in the
embryonic pancreas are likely to be the source of the acinar cell
carcinomas. One Pdx1-tTA; tet-o-PyMT-IRES-Luc mouse with
acinar cell carcinomas also showed b-cell hyperplasia, but in most
cases acinar cell carcinomas apparently arose sooner than b-cell
hyperplasia and overwhelmed the whole pancreas. Unlike PyMT-
induced b-cell hyperplasia, continued expression of PyMT is
required to maintain the viability of the acinar cell carcinomas.
After PyMT de-induction, acinar tumor cells underwent apoptosis
and stopped proliferation, and the pancreas gradually returned to
its normal appearance over 15 weeks. Interestingly, most of the
islets were not enlarged in the pancreata after regression of the
huge acinar cell carcinomas, indicating that pancreata were newly
regenerated.
In the Pdx1-tTA; tet-o-PyMT-IRES-Luc bitransgenic mice that
have never received doxycycline, all epithelial lineages of the
pancreas express PyMT during development. However, neither
non-b-cell endocrine neoplasms nor PanINs have been observed,
even though Pdx1
+ precursors give rise to these cells, and other
oncogene models targeting Pdx1
+ precursors produce PanINs and
infiltrating ductal adenocarcinomas [19]. Our results suggest that
transient expression of PyMT is not adequate for tumor initiation
in a, d, e, pp, and ductal cells.
Figure 5. Effects of de-induction of PyMT and luciferase in the acinar cell carcinomas of Pdx1-tTA; tet-o-PyMT-IRES-Luc bitransgenic
mice. (A) Bioluminescence intensities from 4 Pdx1-tTA; tet-o-PyMT-IRES-Luc bitransgenic mice before and after being placed on doxycycline for 1 to 4
days; each symbol denotes a different mouse. Bioluminescent images of one mouse (represented by &) are shown on the right during induction and
1 and 4 days after addition of doxycycline. (B) De-induction of PyMT in Pdx1-tTA; tet-o-PyMT-IRES-Luc bitransgenic mice with acinar cell carcinomas
causes tumor regression. Hematoxylin and eosin stain of pancreatic sections from Pdx1-tTA; tet-o-PyMT-IRES-Luc bitransgenic mice with strong
luciferase activity (.10
8 photons/sec) before and after being placed on doxycycline for 2, 12, and 15 weeks. Original magnification, 56. The ages of
the mice when sacrificed were indicated.
doi:10.1371/journal.pone.0006932.g005
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delivery has been shown to lead to tumor formation in mammary
glands, endothelial cells, liver, and pancreatic exocrine cells
[7,16,17]. The potency of PyMT is attributed, at least in part, to
its ability to activate MAPK and PI3K/Akt signaling pathways
[8]. It has been shown that PI3K/Akt signaling pathway affects b
cell size and function. Constitutive activation of Akt1 in b cells
increases cell size and decreases blood glucose levels [20,21].
Selective deletion of the phosphatase and tensin homologue,
PTEN, an antagonist of PI3K signaling, in b cells results in a 4.5-
fold increase in total islet area by increasing both cell size and
number [22,23]. Compared to these models, PyMT induces more
extensive b-cell hyperplasia with a ,30-fold increase in islet area
without significant change in cell size and blood glucose level, and
mice do not develop malignant b-cell tumors. It is possible that
some of the signaling molecules modulated by PyMT in the course
of tumorigenesis are not expressed or active in b cells.
Although induction of PyMT does not lead to tumorigenesis in b
cells, even in Ink4a/Arf-null and Arf-null backgrounds, b cells are
subject to transformation by other oncogenes, such as SV40 T
antigen (Tag) and Myc; in addition, the viability of either the
hyperplastic or tumor cells is dependent on the continued
expression of the initiating oncogene [24–26].
Tag provides the driving force for tumor initiation by blocking
the activities of Rb and p53 tumor suppressors [27]. The process of
Tag-induced islet hyperplasia is accompanied by apoptosis, but b
cells generated by proliferation outnumber the apoptotic cells [28].
Importantly, the islet hyperplasia is reversible upon de-induction of
Tag in RIP7-rtTA; tet-o-Tag bitransgenic mice, and the islets are
gradually restored to their normal sizes through apoptosis within 4–
8 weeks after doxycycline removal [24], an outcome different from
our observation in PyMT-induced b-cell hyperplasia.
Activation of Myc in b cells initially causes rapid and
synchronous entry into the cell cycle, but proliferation is
overwhelmed by concomitant induction of apoptosis in transgenic
mice [26]. When Myc is activated in islets that overexpress an anti-
apoptotic molecule, Bcl-xL, b-cell hyperplasia is induced within 7
days and multiple, large invasive b-cell tumors develop after 6
weeks of Myc activation. Both the hyperplasia and the tumors
rapidly regress by apoptosis when Myc is inactivated, indicating
that the survival of these Myc-expanded cell populations is
dependent on continued Myc activity.
Our results with induction and de-induction of PyMT in b cells
differ from results in experiments with several other inducible
transgenic models, affecting various tissues, in which continued
activity of the initiating oncogenes is necessary to maintain cell
viability. Even the survival of metastases, the most advanced stages
of tumorigenesis, has been shown to depend on expression of the
initiating oncogene [29].
Several possibilities might explain why the expanded b cells
induced by PyMT do not regress upon de-induction of PyMT.
First, expression of PyMT may trigger or be accompanied by
additional mutations, epigenetic changes, or alterations in the
microvasculature that are able to prevent regression. Second, b
cells in adult mice have been shown to arise from pre-existing b
cells, not from stem cells [30]. It is likely that PyMT induces
hyperplastic islets through a mechanism similar to b cell
duplication and that these duplicated, differentiated cells do not
depend on the continued expression of PyMT for their viability.
Third, PyMT-induced b-cell hyperplasia has a low proliferation
index (as judged by Ki67 staining: 3.761.5%), compared to acinar
cell carcinomas (46.7612%), Tag-induced b-cell hyperplasia
(21.163%; data not shown), and Myc-induced b-cell hyperplasia
(near 100%) [26]. It is possible that the oncogenic signaling
pathways are dispensable for the survival of slowly proliferating
cells, whereas they are required for the survival of the highly
proliferative cells.
In summary, we have shown that PyMT can induce oncogene-
dependent exocrine tumors from immature pancreatic cells, but
expression of PyMT in the b cell lineage leads to an irreversible
increase in b-cell numbers. Importantly, PyMT-induced b-cell
hyperplasia does not progress to malignant tumor formation.
Blood glucose levels in mice with PyMT-induced b-cell hyperpla-
sia are within normal ranges, indicating the preservation of intact
glucose-sensing capacity in the expanded b-cell population.
Conceivably, understanding the mechanism by which b cells
proliferate in response to PyMT and how expanded islets are
maintained after de-induction of the oncogene might help to
develop strategies to enhance human islet cells expansion in vitro
for transplantation in diabetic patients.
Materials and Methods
Mouse strains, animal husbandry, and genotyping
PyMT DNA (,1.27 kb) was amplified from pBluescript II-
PyMT by PCR using primers containing EcoRI and ClaI sites, and
was then released by EcoRI/ClaI digestion and subcloned into a
EcoRI/ClaI digested TMILA plasmid which contains the tetracy-
cline operator, an internal ribosome entry site (IRES), firefly
luciferase coding region (Luc), and the SV40 polyadenylation
signal [29,31]. The resulting 5.8 kb tet-o-PyMT-IRES-Luc transgene
construct was released from the TMILA vector backbone by
digestion with NotI, purified, and resuspended in TE for
pronuclear injection. The tet-o-PyMT-IRES-Luc transgenic found-
ers were generated on a pure C57BL/6 genetic background. RIP7-
rtTA mice [32] were rederivatived onto a pure C57BL/6 genetic
background. Pdx1-tTA knock-in mice were on an ICR genetic
background [13]. Doxycycline was administered by feeding mice
with doxycycline-impregnated food pellets (625 ppm, Harlan-
Teklad). Mice were housed in accordance with Memorial Sloan-
Kettering Cancer Center (MSKCC) institutional guidelines and all
experiments involving mice were approved by the Institutional
Animal Care and Use Committee at MSKCC. Genotypes were
determined by PCR using mouse tail DNA prepared using
Qiaprep Tail DNeasy isolation kit (QIAGEN) according to the
manufacturer’s instruction. PCR primers were: for PyMT:5 9-
CTGCTACTGCACCCAGACAA-39 and 59-TCCGCCGTTT-
TGGATTATAC-39 (a 468-bp product); for rtTA:5 9-GTG-
AAGTGGGTCCGCGTACAG-39 and 59-GTACTCGTCAA-
TTCCAAGGGCTCG-39 (a ,450-bp product); and for tTA:5 9-
TAGAAGGGGAAAGCTGGCAAGATT-39 and 59-CCGCGG-
GGAGAAAGGACA-39 (a 540-bp product).
in vivo bioluminescent imaging
Mice were anesthetized with 3% isoflurane and with shaved
abdomen received a retro-orbital injection with 50 ml of 30 mg/ml
D-luciferin (Caliper Life Sciences, XR-1001). Images were
acquired for 2 min using Xenogen IVIS 100 system with Living
Image 2.50 software. A photographic image of the mouse was
taken, onto which the pseudocolor image representing the spatial
distribution of photon counts was projected. We defined a circular
region around the pancreas and used it as a standard in all
experiments. From the region, the photo counts were compared
among mice.
Histology and immunohistochemical analysis
Tissues were removed and fixed in 10% buffered formalin
overnight at room temperature. Fixed tissues were processed and
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Formalin-fixed/paraffin-embedded sections were deparaffinized
and rehydrated by passage through a graded xylene/ethanol series
before staining. Immunochemistry with VECTASTAIN Elite
ABC Kit (Vector Laboratories) was performed according to the
manufacturer’s instructions. Primary antibodies used were anti-
insulin (Immunostar, 1:600), anti-synaptophysin (DAKO, 1:100),
anti-glucagon (Novocastra, 1:1,000), anti-somatostatin (DAKO,
1:10,000), anti-activated caspase 3 (Cell Signaling, 1:100), anti-
Ki67 (Novocastra, 1:1,000), anti-phospho-Erk (Cell Signaling,
1:100), anti-Erk (Cell Signaling, 1:100), anti-phospho-Akt (Cell
Signaling, 1:100), and anti-phospho-S6 ribosomal protein (Cell
Signaling, 1:200).
Western blot analysis
Pancreata were perfused and digested into small pieces with
collagenase (Sigma) at 37uC for 15 min, and were centrifuged in a
Ficoll gradient (11%, 20.5%, 23%, and 25% (w/v)) as described
[33]. Islets in the top three layers of the gradient were collected.
To prepare protein extracts, islets were homogenized with pellet
pestles (Kontes) in Eppendorf tubes and lysed in buffer containing
100 mM NaCl, 100 mM Tris (pH 8.2), 0.5% NP-40, and inhibitor
cocktail for proteases and phosphatases at 4uC. The cellular debris
was pelleted at the top speed in a microcentrifuge for 10 min at
4uC, and the supernatant was transferred to new tubes. 20 mg total
proteins were separated by SDS-PAGE and transferred onto
nitrocellulose membranes. The membranes were stained with
Ponceau S and immunoblotted with the following antibodies: anti-
PyMT (1:5,000), anti-phospho-Erk (Cell Signaling, 1:1,000), anti-
Erk (Cell Signaling, 1:1,000), anti-phospho-Akt (Cell Signaling,
1:250), anti-Akt (Cell Signaling, 1:1,000), and appropriate
secondary antibodies. The signals were detected with ECL
chemiluminescent substrate (GE Healthcare).
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